Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role. Issue 6 (3rd June 2017)

• Record Type: Journal Article
• Authors: Bozzo, Jordi; Jorquera, Juan I.
• Is Part Of: Expert review of anti-infective therapy. Volume 15:Issue 6(2017)
• Page Start: 585
• Page End: 604
• Publication Date: 2017-06-03
• Subjects: Emerging disease -- immunoglobulin -- infection -- outbreak -- plasma -- serum; Anti-infective agents -- Research -- Periodicals; 616.90461
• DOI: 10.1080/14787210.2017.1328278
• Languages: English
• ISSNs: 1478-7210

Abstract

ABSTRACT: Introduction : Pooled human immunoglobulins (IGs) are prepared from plasma obtained from healthy donors as a concentrated antibody-containing solution. In addition, high-titer IGs (hyperimmune) against a specific pathogen can be obtained from vaccinated or convalescing donors. Currently, IGs can be used for the treatment of a variety of infections for which no specific therapy exists or that remain difficult to treat. Moreover, the recent pathogen outbreaks for which there is no approved treatment have renewed attention to the role of convalescent plasma and IGs. Areas covered : In this review, a historical perspective of the use of sera and IGs in humans as anti-infective agents (any viral, bacterial, parasitic infection), excluding immunodeficient patients, is presented from early development to the latest clinical studies. A Medline search was conducted to examine the peer-reviewed literature, with no date limits. Expert commentary : Human pooled plasma-derived IG products benefit from the polyclonal response of every individual donor and from the interindividual variability in such response. The trend to increased availability of vaccines for infectious diseases also opens new potential applications of hyperimmune IGs for emerging or re-emerging infectious diseases (e.g.: Ebola, Zika, Dengue), for the prevention and treatment in the general population, healthcare personnel and caregivers.